Bio Integrates 2023 Track 3
PREDICTION
If only we all had a crystal ball…
Fireside Chat
Fireside Chat
Camilla Easter | Chief Executive Officer | Oxford Medical Products
Vineeta Tripathi | Chief Executive Officer, Chief Scientific Officer | Vitarka Therapeutics
Lydia Mapstone | Chief Executive Officer and Co-founder | BoobyBiome
Interviewed by
Martino Picardo | Chairman | Discovery Park
Location, location, location
How much impact does this have on your success? How to choose the right site for your business.
FACILITATED BY
Mayer Schreiber | Chief Executive Officer | Discovery Park
PANELLISTS
Toby Reid | Executive Director | We are Pioneer Group
Sally Ann Forsyth OBE | Chief Executive Officer | Stevenage Bioscience Catalyst
Rich Ferrie | Chief Executive Officer | London BioInnovation Centre Ltd
Nuno Alves | Associate Director, Innovation Management | Astellas Europe
Charles Walford | Director | Stanhope
To AI or not to AI? That’s the question…
Is AI helpful to all biotechs? When to apply it, how to apply it, do you know what it is?
FACILITATED BY
Kevin Cox | Chair | Biorelate
PANELLISTS
Justin Bryans | Chief Scientific Officer (Early Discovery) | Charles River Laboratories
Mark Hughes | Vice President of Sales & Marketing | Biorelate
Daniel Veres | Chief Scientific Officer & Co-Founder | Turbine
Dean Plumbley | CTO and Head of AI | CoSyne Therapeutics
Joseph Day | Business Development (Data/AI) | Cancer Research Horizons
Get it right first time
How to decide the right [partnering] strategy to overcome the challenges of getting a first-in-class / new therapeutic modality to the market first time.
FACILITATED BY
Tauhid Ali | Co-Founder and Board Director | Oak Hill Bio
PANELLISTS
Neil Jones | Chief Commercial Officer | Aenova Group
Helen Barker | Vice President, Global Tech Ops & CMC | Reneo Pharmaceuticals
Joachim Luithle | Co-Founder | BioLink Intelligence
Justin Bryans | Chief Scientific Officer (Early Discovery) | Charles River Laboratories
Fishing in a bigger pond – how to reel in the money
As tech and other investors, including general/retail, look to biotech and the Life Sciences, how does biotech compete with other LS sectors – and how do you keep these investors happy?
FACILITATED BY
Nathan Sigworth | Co-founder and Chief Executive Officer | CCX
PANELLISTS
Bradley Hardiman | Head of UK/EU Search & Evaluation, | Astellas Pharmaceuticals
Irene Graham OBE | Founding CEO and Board Director | ScaleUp Institute
Suzanne Dilly | Chief Executive Officer | ValiRx PLC
Uzma Choudry | Venture Capital Investor | Octopus Ventures
Alex Brown | Sr. Investment Associate | 24Haymarket
Emerging technologies for improving drug and vaccine development for infectious disease
How quickly is the discovery landscape shifting towards new modalities and what challenges do these present for the clinical trials and regulatory systems?
Has the way we handled COVID therapeutics generated long term change in the discovery, development and regulatory systems?
FACILITATED BY
Janet Hemingway CBE | Professor of Tropical | Liverpool School of Tropical Medicine
PANELLISTS
Juliana Haggerty | Head of Centre of Excellence – Lipid Nanoparticles | CPI
Clare Bryant | Professor | The University of Cambridge
Joshua Blight | Chief Executive Officer & Co-Founder | Baseimmune
Philip Cruz | Country Medical Director, UK | Moderna